Collaboration with Oncology and Evolution of Targeted Therapies

<p>Ask the Experts: A Lifelong Learning Series - October 2021<br> Collaboration with Oncology and Evolution of Targeted Therapies</p> <p>John H. Shin, MD<br> C. Rory Goodwin, MD, PhD<br> Joshua C. Patt, MD, MPH</p> <p>Disclosures:</p> <p>Goodwin, C. Rory: Consulting: Medtronic (B); Grants: Federal Food And Drug Administration (G, Paid directly to institution/employer), NIH/NINDS (F, Paid directly to institution/employer), Robert Wood Johnson Foundation (F, Paid directly to institution/employer).</p> <p>Patt, Joshua &nbsp;C.: Board of Directors: AOA (Nonfinancial, Council of Orthopaedic Residency Directors Chair, Executive Committee Member).</p> <p>Shin, John H.: Consulting: Carbofix (None), DePuy (B), Medtronic (A), NuVasive (B).</p> <p><br></p> <p>Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+</p>